Monday, November 16, 2026Latest
Money

Top pharma firms sustain growth despite energy disruptions

Leading pharmaceutical companies in Bangladesh maintained revenue and profit growth during the July-September quarter of FY27, despite ongoing disruptions in gas and electricity supplies and rising fuel costs. While expansion slowed to mostly single-digit rates, top-tier firms like Square Pharmaceuticals, Beximco Pharmaceuticals, and Renata reported increases in both metrics, demonstrating resilience against macroeconomic pressures.

Square Pharma led with Tk2,244 crore in consolidated revenue, up 4%, and a 5% rise in net profit. Renata saw its profit jump 38% to Tk102 crore, while Beacon Pharma recorded the fastest revenue growth at 13%. Conversely, ACI Pharmaceuticals swung to a loss of Tk18.84 crore due to higher finance costs, and Advent Pharma's earnings dropped 60%, highlighting a widening gap between operators with strong balance sheets and those struggling with inflation.

The sector's market capitalisation stands at Tk40,995 crore, accounting for 6.11% of the Dhaka Stock Exchange's total value. Analysts suggest a defensive strategy for investors, focusing on blue-chip drug makers with robust export capabilities and proven resilience against energy and currency fluctuations, as these firms continue to offer stable long-term fundamentals amid short-term utility shocks.

Read the full story at tbsnews.net.

Leave a Reply